|Day Low/High||135.75 / 140.24|
|52 Wk Low/High||118.62 / 148.99|
Stocks in the health care sector seem to have no underpinnings whatsoever.
The debt-laden drugmaker needs to shore up cash, but a Salix sale might be too rash a move.
We have to ask: where is the cash flow to pay off the debt, if any important prices are rolled back?
Since mid- July there have been numerous negative divergences. One clear example is the chart below of new highs. During this three-and-a-half month period the S&P 500 has traded in a range above 2125 (the post-Brexit breakout). Downside attempts li...
For starters, trouble for banks, drugs, energy and M&A.
Jim Cramer reflects on a dramatic day of selling on Wall Street that forever changed the industry.
"I've never seen so many men wasted so badly." -- Blondie in The Good, the Bad and the Ugly." And now it's time to run down "The Good, the Bad and the Ugly" ... The Good The market was up from the get-go. (T)FANG is the world's fair. High beta was...
Back at morning highs and facing mild resistance at S&P 500 Index 2145/2149. WTI above $50 seems to put a bid under stocks, below $50 not so much. Stocks here and across the pond helped by rumors that sovereign funds may buy more equities. Volume a ...
U.S. stocks held higher as a series of positive earnings reports filtered in on Tuesday. Netflix boosted the Nasdaq, while Goldman Sachs pushed the Dow Jones Industrial Average higher.
On Tuesday, October 18, Goldman Sachs (GS) and Yahoo! (YHOO) release quarterly results.
In "The Market Outlook Worsens," I made the following observations: When I throw in a dose of the following headwinds, the stage could be set for a difficult three to nine months for the capital markets: Overvaluation, with 25x GAAP and 19x non-GAA...
Investors will get a slew of earnings reports from major companies and a host of Federal Reserve speakers during the week of Oct. 17.
The dual recall of both new and replacement Galaxy Note7 phones has left Samsung Electronics shares in tatters.
Pay attention to what companies are doing to improve themselves, not the hand-wringing from fund managers about Fed intervention.
It could well be the stock market, not the Fed, that is driving our retail and services.
Its long-term reputation appears to be supporting the shares far more than they deserve.
Be aware that Johnson & Johnson, American Electric Power and Federal Realty don't roll over idly.
Zimmer Biomet is on track to return to growth, which could signal more mergers and acquisitions within the industry.
There are plenty of doubters about the market and its record highs.
Valeant could rake in more than $1 billion annually in new sales after FDA approval of a key drug.
Better-than-expected earnings from Johnson & Johnson pushed the Dow Jones Industrial Average to close out the day with another record.
It depends on the type of test and who's doing the grading.
A rush of earnings kept investors busy throughout the morning. Netflix was one of the biggest drags on the Nasdaq and S&P 500.
Johnson & Johnson's earnings reveal just how impressive growth is at the big pharma company, according to Jim Cramer.
The health care giant's quarterly earnings and sales clocked in well above analyst expectations.
Netflix underwhelmed analysts as subscriber growth came up short.
On Tuesday, July 19, investors will focus on the U.S. banking sector when Goldman Sachs reports second quarter results.